League table for failure to achieve the FDA-recommended endpoint to define treatment response
| Alosetron 1 mg twice daily | |||||
| 0.89 (0.72 to 1.10) | Ramosetron 2.5 µg once daily | ||||
| 0.80 (0.69 to 0.93) | 0.90 (0.77 to 1.05) | Eluxadoline 100 mg twice daily | |||
| 0.78 (0.67 to 0.91) | 0.88 (0.75 to 1.03) | 0.98 (0.91 to 1.05) | Eluxadoline 75 mg twice daily | ||
| 0.75 (0.64 to 0.89) | 0.85 (0.72 to 1.00) | 0.94 (0.87 to 1.02) | 0.97 (0.89 to 1.05) | Rifaximin 550 mg twice daily | |
| 0.69 (0.60 to 0.80) | 0.78 (0.67 to 0.91) | 0.87 (0.83 to 0.91) | 0.89 (0.84 to 0.94) | 0.92 (0.86 to 0.98) | Placebo |
Relative risk with 95% CI in parentheses. Comparisons, column versus row, should be read from left to right and are ordered relative to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects.
Boxes shaded green denote a statistically significant difference.